Eyedrop Vaccination Induced Systemic and Mucosal Immunity against Influenza Virus in Ferrets.

337 432

Cited 5 times in

Authors: Sangchul Yoon ; Eun-Do Kim ; Min-Suk Song ; Soo Jung Han ; Tae Kwann Park ; Kyoung Sub Choi ; Young-Ki Choi ; Kyoung Yul Seo

MeSH: Administration, Intranasal ; Animals ; Ferrets/immunology* ; Ferrets/virology* ; Immunity, Mucosal/drug effects* ; Influenza Vaccines/administration & dosage ; Influenza Vaccines/immunology* ; Lung/immunology ; Lung/pathology ; Lung/virology ; Ophthalmic Solutions/pharmacology* ; Orthomyxoviridae/drug effects ; Orthomyxoviridae/immunology* ; Orthomyxoviridae Infections/diagnostic imaging ; Orthomyxoviridae Infections/immunology ; Orthomyxoviridae Infections/prevention & control ; Orthomyxoviridae Infections/virology ; Tomography, X-Ray Computed ; Vaccination* ; Vaccines, Attenuated/administration & dosage ; Vaccines, Attenuated/immunology*

Abstract: We investigated eyedrop vaccination (EDV) in pre-clinical development for immunological protection against influenza and for potential side effects involving ocular inflammation and the central nervous system (CNS). Live attenuated influenza EDV, CA07 (H1N1), PZ-4 (H1N2) and Uruguay (H3N2), induced both systemic and mucosal virus-specific antibody responses in ferrets. In addition, EDV resulted in a clinically significant protection against viral challenge, and suppression of viral replication in nasal secretion and lung tissue. Regarding safety, we found that administered EDV flow through the tear duct to reach the base of nasal cavity, and thus do not contact the olfactory bulb. All analyses for potential adverse effects due to EDV, including histological and functional examinations, did not reveal significant side effects. On the basis of these findings, we propose that EDV as effective, while being a safe administration route with minimum local side effects, CNS invasion, or visual function disturbance.